The Immune Response Corporation Granted U.S. Patent for the Use of Antibodies To Target T Cell Receptors to Treat Rheumatoid Arthritis

Apr 26, 2001, 01:00 ET from The Immune Response Corporation

    CARLSBAD, Calif., April 26 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) announced today that it was awarded United States Patent Number
 6,221,352 that covers claims relating to the use of antibodies to target
 specific T Cell Receptors (TCRs) to treat rheumatoid arthritis.  Specifically,
 the new patent covers the administration of monoclonal antibodies, alone
 and/or coupled to cytotoxic or cytostatic agents, that selectively bind to and
 prevent the proliferation of T Cells that express either Vbeta 14 or Vbeta
 17 TCRs.  These Vbeta 14 and Vbeta 17 T Cells serve as good targets for
 treating rheumatoid arthritis because they are among the over-expressed
 pathogenic T Cells thought to cause the disease.  The Company believes that
 selectively targeting these "fingerprint" TCRs may help reduce the population
 of pathogenic T Cells and prevent further tissue damage in people suffering
 from rheumatoid arthritis.
     "Approaches utilizing monoclonal antibodies are emerging in the
 marketplace as new options for treating human diseases, including autoimmune
 diseases such as rheumatoid arthritis," said Richard M. Bartholomew, Ph.D.,
 Executive Director of Research Operations for The Immune Response Corporation.
 "This patent allows us to utilize antibodies, either alone or coupled to
 chemotherapeutic or radioactive moieties, to target pathogenic T Cells for the
 treatment of rheumatoid arthritis.  This is a valuable extension of our core
 technology on TCRs as therapeutic targets in autoimmune disease."
     On March 30, 2001, the Company announced the issuance of U.S. Patent
 Number 6,207,645, which covers vaccination of individuals with rheumatoid
 arthritis using DNA vaccines designed to synthesize the key Vbeta TCR
 peptides.  The Company also announced on August 9, 2000, that it was issued
 U.S. Patent Number 6,090,387 for vaccinating individuals with rheumatoid
 arthritis using the specific Vbeta TCR peptides.
     The Immune Response Corporation's Vbeta TCR peptide vaccine, RAVAX(TM),
 has completed two Phase II clinical trials, exhibiting safety and a
 statistically significant treatment effect in individuals with rheumatoid
 arthritis.  The Company has also carried out clinical trials using its core
 TCR peptide technology towards the development of investigational immune-based
 therapies to treat other autoimmune diseases, including multiple sclerosis and
 psoriasis.
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News On-
 Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether preclinical data can be replicated in
 clinical trials, whether if initiated clinical trials will be successfully
 concluded and whether a preventative vaccine will be approved for marketing or
 be successfully commercialized.  Those factors are discussed more thoroughly
 in The Immune Response Corporation's SEC filings, including but not limited to
 its report on Form 10-K for the year ended December 31, 2000.  The Company
 undertakes no obligation to publicly release the result of any revisions to
 these forward-looking statements which may be made to reflect events or
 circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X31554977
 
 

SOURCE The Immune Response Corporation
    CARLSBAD, Calif., April 26 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) announced today that it was awarded United States Patent Number
 6,221,352 that covers claims relating to the use of antibodies to target
 specific T Cell Receptors (TCRs) to treat rheumatoid arthritis.  Specifically,
 the new patent covers the administration of monoclonal antibodies, alone
 and/or coupled to cytotoxic or cytostatic agents, that selectively bind to and
 prevent the proliferation of T Cells that express either Vbeta 14 or Vbeta
 17 TCRs.  These Vbeta 14 and Vbeta 17 T Cells serve as good targets for
 treating rheumatoid arthritis because they are among the over-expressed
 pathogenic T Cells thought to cause the disease.  The Company believes that
 selectively targeting these "fingerprint" TCRs may help reduce the population
 of pathogenic T Cells and prevent further tissue damage in people suffering
 from rheumatoid arthritis.
     "Approaches utilizing monoclonal antibodies are emerging in the
 marketplace as new options for treating human diseases, including autoimmune
 diseases such as rheumatoid arthritis," said Richard M. Bartholomew, Ph.D.,
 Executive Director of Research Operations for The Immune Response Corporation.
 "This patent allows us to utilize antibodies, either alone or coupled to
 chemotherapeutic or radioactive moieties, to target pathogenic T Cells for the
 treatment of rheumatoid arthritis.  This is a valuable extension of our core
 technology on TCRs as therapeutic targets in autoimmune disease."
     On March 30, 2001, the Company announced the issuance of U.S. Patent
 Number 6,207,645, which covers vaccination of individuals with rheumatoid
 arthritis using DNA vaccines designed to synthesize the key Vbeta TCR
 peptides.  The Company also announced on August 9, 2000, that it was issued
 U.S. Patent Number 6,090,387 for vaccinating individuals with rheumatoid
 arthritis using the specific Vbeta TCR peptides.
     The Immune Response Corporation's Vbeta TCR peptide vaccine, RAVAX(TM),
 has completed two Phase II clinical trials, exhibiting safety and a
 statistically significant treatment effect in individuals with rheumatoid
 arthritis.  The Company has also carried out clinical trials using its core
 TCR peptide technology towards the development of investigational immune-based
 therapies to treat other autoimmune diseases, including multiple sclerosis and
 psoriasis.
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News On-
 Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether preclinical data can be replicated in
 clinical trials, whether if initiated clinical trials will be successfully
 concluded and whether a preventative vaccine will be approved for marketing or
 be successfully commercialized.  Those factors are discussed more thoroughly
 in The Immune Response Corporation's SEC filings, including but not limited to
 its report on Form 10-K for the year ended December 31, 2000.  The Company
 undertakes no obligation to publicly release the result of any revisions to
 these forward-looking statements which may be made to reflect events or
 circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X31554977
 
 SOURCE  The Immune Response Corporation

RELATED LINKS

http://www.imnr.com